Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.

Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.

Item
http://www.wikidata.org/entity/Q38183850
Treatment of Exudative Age-related Macular Degeneration: Focus on AfliberceptThe role of aflibercept in the management of diabetic macular edemaTransfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheepMolecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approachTherapeutic Options in Refractory Diabetic Macular Oedema.Suppressed endothelin-1 by anti-VEGF therapy is important for patients with BRVO-related macular edema to improve their vision.The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic SubjectsComplications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option.Ischaemic stroke after exposure to aflibercept: interaction with vitamin K antagonist and/or direct pharmacodynamic effect?Mystery of Retinal Vein Occlusion: Vasoactivity of the Vein and Possible Involvement of Endothelin-1.Management of diabetic macular edema in Japan: a review and expert opinion.Aflibercept Versus Bevacizumab and/or Ranibizumab for Recurrent Macular Edema Secondary to Central Retinal Vein Occlusion.Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration.Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment.
P2860

Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.

Item
http://www.wikidata.org/entity/Q38183850
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Pharmacokinetics, pharmacodyna ...... hthalmic drugs that bind VEGF.
@en
type
label
Pharmacokinetics, pharmacodyna ...... hthalmic drugs that bind VEGF.
@en
prefLabel
Pharmacokinetics, pharmacodyna ...... hthalmic drugs that bind VEGF.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Pharmacokinetics, pharmacodyna ...... hthalmic drugs that bind VEGF.
@en
P2093
P2860
P304
P31
P356
10.1586/17512433.2014.884458
P407
P433
P478
P577
P698